Complement Inhibitor Slowed Kidney Decline in IgA Nephropathy

Complement Inhibitor Slowed Kidney Decline in IgA Nephropathy

Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued approval was contingent on demonstrating slowed kidney decline. Fewer participants in the iptacopan group reached the composite kidney-failure endpoint. Iptacopan (Fabhalta) slowed kidney function decline in adults with…

Read More